Clinical significance of braf mutation in thyroid papillary cancer

Otolaryngology - Head and Neck Surgery (United States)

Volumn 148, Issue 6, 2013, Pages 919-925

  Fernandez, Ignacio J ^a   Piccin, Ottavio ^a   Sciascia, Silvia ^a   Cavicchi, Ottavio ^a   Repaci, Andrea ^a   Vicennati, Valentina ^a   Fiorentino, Michelangelo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

BRAF mutation; Papillary thyroid cancer; Prognostic markers; Thyroid cancer; Thyroid surgery

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BODY MASS; BRAF GENE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CHILD; DISEASE FREE SURVIVAL; FEMALE; GENE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; THYROID PAPILLARY CARCINOMA; THYROID SURGERY; ANALYSIS OF VARIANCE; BRAF MUTATION; CARCINOMA; COMPARATIVE STUDY; CONFIDENCE INTERVAL; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; MUTATION; NONPARAMETRIC TEST; PAPILLARY THYROID CANCER; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSTIC MARKERS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL MODEL; SURVIVAL RATE; THYROID CANCER; THYROID TUMOR; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

B RAF KINASE; BRAF PROTEIN, HUMAN; DNA;

BRAF MUTATION; PAPILLARY THYROID CANCER; PROGNOSTIC MARKERS; THYROID CANCER; THYROID SURGERY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARCINOMA; CASE-CONTROL STUDIES; CHILD; CONFIDENCE INTERVALS; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; THYROID NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

MLCS; MLOWN;

EID: 84880427006     PISSN: 01945998     EISSN: 10976817     Source Type: Journal    
DOI: 10.1177/0194599813481942     Document Type: Article

References (25)

1. Nucera C, Goldfarb M, Hodin R, et al. Role of B-Raf (V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf (V600E). Biochim Biophys Acta. 2009;1795:152-161.
2. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003; 88:5399-5404.
3. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell. 2004;6:313-319.
4. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28:742-762.
5. Caronia LM, Phay JE, Shah MH. Role of BRAF in thyroid oncogenesis. Clin Cancer Res. 2011;17:7511-7517.
6. Tufano RP, Teixeira GV, Bishop JB, Carson KA, Xing M. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment a systematic review and meta-analysis. Medicine. 2012;91:1-13.
7. Elisei R, Ugolini C, Viola D, et al. BRAF V600E mutation and outcome of patients with papillary thyroid carcinoma: 15-year median follow-up study. J Clin Endocrinol Metab. 2008;93:3943-3949.
8. Kim S, Lee KE, Myong JS, et al. BRAFV600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg. 2012;36:310-317.
9. Ricarte-Filho J, Ganly I, Rivera M, et al. Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension. Thyroid. 2012;22:575-584.
10. Tufano RP, Bishop J, Wu G. Reoperative Central compartment dissection for patients with recurrent/persistent papillary thyroid cancer: efficacy, safety, and the association of the BRAF mutation. Laryngoscope. 2012;122:1634-1640.
11. Nucera C, Lawler J, Hodin R, Parangi S. The BRAFV600E mutation: what is it really orchestrating in thyroid cancer?. Oncotarget. 2010;1:751-756.
12. Mesa C Jr, Mirza M, Mitsutake N, et al. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res. 2006; 66:6521-6529.
13. Ahn D, Park JS, Sohn JH, et al. BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma. Auris Nasus Larynx. 2012;39:198-203.
14. Pelttari H, Schalin-Ja Ntti C, Arola J, Lo Yttyniemi E, Knuutila S, Va Lima Ki MJ. BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients. APMIS. 2011;120:380-386.
15. Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 2007;246:466-471.
16. Koperek O, Komauth C, Capper D, et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol. 2002;36:844-850.
17. Ward LS, Morari EC, Leite JL, et al. Identifying a risk profile for thyroid cancer. Arq Bras Endocrinol Metabol. 2007;51:713-722.
18. Kim HJ, Kim NK, Choi JH, et al. Associations between body mass index and clinico-pathological characteristics of papillary thyroid cancer. Clin Endocrinol (Oxf). 2013;78(1):134-140.
19. Rinaldi S, Lise M, Clavel-Chapelon F, et al. Body size and risk of differentiated thyroid carcinomas: findings from the EPIC study. Int J Cancer. 2012;131:1004-1014.
20. Fugazzola L, Puxeddu E, Avenia N, et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer. 2006; 13:455-464.
21. Horwell GM, Carty SE, Amstrong MJ, et al. Both BRAF V600E mutation and older age (.65 years) are associated with recurrent papillary thyroid cancer. Ann Surg Oncol. 2011; 18:3566-3571.
22. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid. Cancer. 2007;110:38-46.
23. Kim TH, Park YJ, Lim JA, et al. The association of the BRAF V600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer. Cancer. 2012;118:1764-1773.
24. Park YJ, Kim YA, Lee YJ, et al. Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAF (V600E) mutation, clinicopathological features, and immunohistochemical findings. Head Neck. 2010;32:38-45.
25. Niemeier LA, Kuffner Akatsu H, Song C, et al. A combined molecular-pathological score improves risk stratification of thyroid papillary microcarcinoma. Cancer. 2012;118:2069-2077.